As millions turn to GLP-1 medications like Ozempic and Mounjaro to reshape their bodies, science is confronting an unintended consequence: the quiet erosion of muscle alongside fat. A new drug, apitegromab, has shown early promise in preserving lean tissue during weight loss, raising the possibility that the body need not pay so steep a price for transformation. The finding invites a deeper question about what it means to lose weight well — not merely less of oneself, but less of the wrong parts.
G1
· Jun 09, 2026
· health
· 3 min de lectura
Medium
Verificación: Caracterizado
Novo medicamento apitegromab pode reverter perda muscular de Ozempic
◉
Health & Medicine
2746 artículos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% coincidencia
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% coincidencia
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% coincidencia
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% coincidencia
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% coincidencia
Cobertura Relacionada
G1 · Aug 20
Pai agradece médicos após morte de gêmeas unidas pela cabeça: 'mais vitórias que derrotas'
Pai das gêmeas unidas pela cabeça que morreram em cirurgia de separação agradece empenho de mais de 50 profissionais do …
Folha de S.Paulo · Aug 20 Selton Mello se emociona ao receber Kikito de Cristal em GramadoSelton Mello recebeu o Kikito de Cristal no Festival de Gramado e se emocionou ao lembrar que era a primeira vez receben…
G1 · Aug 20 CEMEI Amiguinhos da Vila inaugura prédio moderno com capacidade para 320 alunosInaugurado novo prédio do CEMEI Amiguinhos da Vila em Montes Claros, com capacidade para 320 alunos, oito salas de aula,…
Folha de S.Paulo · Aug 20 Hepatites D e E circulam no Brasil e preocupam especialistasRevisão de 200 estudos com dados de 14,5 milhões de pessoas revela que hepatites D e E circulam no Brasil com prevalênci…
Sesgo y Encuadre
⚖
Article presents promising research on apitegromab for muscle preservation in GLP-1 users with balanced skepticism, though relies heavily on colloquial framing and limited study details.
Bias Direction
center-left
Confidence
MED
Sensationalized colloquial framing ('bumbum de Ozempic') combined with cautious scientific reporting. Uses popular terminology to engage readers while maintaining expert skepticism about efficacy claims.
'bumbum de Ozempic' (repeated 4 times)
'canetas emagrecedoras' (weight-loss pens - diminutive/colloquial)
'bumbum mais achatado ou flácido' (flattened/flaccid buttocks - descriptive language emphasizing aesthetic concern)
'efeito colateral' (side effect - frames as negative)
Voices of actual patients experiencing the phenomenon
Perspective from manufacturers (Novo Nordisk, Eli Lilly) on the issue
Nutritionists' or fitness experts' detailed guidance on prevention
Cost-benefit analysis comparing apitegromab treatment to exercise/nutrition interventions
Long-term safety data or expert commentary on apitegromab beyond 'more studies needed'
Impacto Geopolítico
🌎
Medical research on muscle-preserving drug has no geopolitical implications; this is a pharmaceutical/health article with no international relations, conflict, or power dynamics.
Escalation Risk
low
Confidence
HIGH
Lente Económico
📈
Apitegromab shows promise in preserving muscle mass during GLP-1 weight-loss treatment, addressing a significant side effect where up to one-third of weight loss comes from muscle rather than fat.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Cosmetic Surgery
Fitness/Wellness Industry
Obesity Treatment Market
Consumers using GLP-1 drugs (Ozempic, Wegovy, Mounjaro) could benefit from improved outcomes with reduced muscle loss and body composition changes. This addresses aesthetic and health concerns, potentially increasing treatment adherence and satisfaction. May reduce demand for cosmetic procedures to address 'Ozempic butt' side effects.
Regulatory agencies (FDA, ANVISA) will need to evaluate apitegromab's efficacy and safety through additional clinical trials before approval. Healthcare systems may need to update obesity treatment guidelines to include combination therapies. Insurance coverage decisions will impact accessibility and market adoption of combination treatments.